Using a Transection Paradigm to Enhance the Repair Mechanisms of an Investigational Human Cell Therapy

Monica J. Chau¹,², Jorge E. Quintero¹,²,³, Paula V. Monje⁴, Stephen Randal Voss³, Andrew S. Welleford⁵, Greg A. Gerhardt¹,²,³, and Craig G. van Horne¹,²,³

Abstract
One promising strategy in cell therapies for Parkinson’s disease (PD) is to harness a patient’s own cells to provide neuroprotection in areas of the brain affected by neurodegeneration. No treatment exists to replace cells in the brain. Thus, our goal has been to support sick neurons and slow neurodegeneration by transplanting living repair tissue from the peripheral nervous system into the substantia nigra of those with PD. Our group has pioneered the transplantation of transection-activated sural nerve fascicles into the brain of human subjects with PD. Our experience in sural nerve transplantation has supported the safety and feasibility of this approach. As part of a paradigm to assess the reparative properties of human sural nerve following a transection injury, we collected nerve tissue approximately 2 weeks after sural nerve transection for immunoassays from 15 participants, and collected samples from two additional participants for single nuclei RNA sequencing. We quantified the expression of key neuroprotective and select anti-apoptotic genes along with their corresponding protein levels using immunoassays. The single nuclei data clustered into 10 distinctive groups defined on the basis of previously published cell type-specific genes. Transection-induced reparative peripheral nerve tissue showed RNA expression of neuroprotective factors and anti-apoptotic factors across multiple cell types after nerve injury induction. Key proteins of interest (BDNF, GDNF, beta-NGF, PDGFB, and VEGF) were upregulated in reparative tissue. These results provide insight on this repair tissue’s utility as a neuroprotective cell therapy.

Keywords
cell therapy, tissue-based therapy, peripheral nerve, single nuclei RNA sequencing, neuroprotection

Introduction
The use of human embryonic and neural stem cells has limitations as cell therapies for Parkinson’s disease (PD)¹⁻³. Obtaining embryonic or fetal cells can be ethically challenging, and embryos for transplantation are not always readily available¹,²,⁴. Furthermore, they are not autologous tissues and require the patient to use immunosuppressing drugs. Other stem cell sources include autologous induced pluripotent stem (iPS) cells differentiated into dopaminergic progenitors; however, their use in clinical testing in PD is still in its infancy⁵. In addition, incompletely reprogrammed cells can elicit harmful immune responses⁶,⁷. A more feasible approach could be to use the body’s own repair mechanisms. Autologous tissue, like peripheral nerve, has robust repair capabilities, is readily available, and can be efficiently procured⁸,⁹. Our strategy is to harness the patient’s own reparative peripheral nerve tissue and

¹ Brain Restoration Center, College of Medicine, University of Kentucky, Lexington, KY, USA
² Department of Neurosurgery, College of Medicine, University of Kentucky, Lexington, KY, USA
³ Department of Neuroscience, College of Medicine, University of Kentucky, Lexington, KY, USA
⁴ Stark Neurosciences Research Institute, Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
⁵ Department of Neurology, College of Medicine, University of Kentucky, Lexington, KY, USA

Submitted: February 14, 2022. Revised: July 12, 2022. Accepted: August 16, 2022.

Corresponding Author:
Craig G. van Horne, Department of Neurosurgery, College of Medicine, University of Kentucky, 780 Rose Street, Lexington, KY 40536, USA. Email: craigvanhorne@uky.edu
implant it to provide neuroprotection to areas of the brain affected by neurodegenerative disease.

After injury, cells in the peripheral nervous system (PNS) undergo a highly orchestrated transformation to regenerate and re-establish function to the extremities. As part of an investigational cell therapy that we are currently trialing, we implanted active reparative peripheral nerve tissue into the substantia nigra of participants with PD. No treatment exists to repair damaged brain cells; thus, our goal was to slow neurodegeneration by implanting reparative living cells into the substantia nigra.

Cell therapy strategies can affect disease progression either by replacing dead or dying cells, or by promoting cell survival and neuroprotection via secretion of paracrine and neurotrophic factors. Implanted peripheral nerve tissue would not replace sick neurons of the central nervous system, but could provide neuroprotective, anti-inflammatory, anti-apoptotic, and pro-regenerative factors to support dying cells. Furthermore, implanting autologous peripheral nerve tissue has the major advantages of being readily obtainable from patients and circumventing host immune rejection. If obtained from a sensory nerve like the sural nerve, the side effects, if any, are mostly paresthesias and hypesthesia in cutaneous distribution of the nerve. In our previous studies, participants have reported that these incidents were not bothersome in the long term.

An ideal cell therapy against neurodegeneration would be robust enough to slow disease progression by providing neuroprotective, anti-apoptotic, and anti-inflammatory support to unhealthy cells while maintaining its potency from harvesting through deployment. Our approach has been to implant a supportive milieu of neuroprotective factors with the expectation that a combination of factors is more durable and effective than using a single neuroprotective factor therapy. In addition, we have used peripheral nerve fascicles rather than single cell products (e.g., Schwann cells) that have been used in nonclinical rodent and non-human primate animal models. To date, definitive trials of single-neuroprotective factor therapy, for example, glial-cell derived neurotrophic factor (GDNF), have shown mixed results in slowing PD progression. The survival of neural stem cells after transplantation is limited as a proportion of cells die within days after transplantation into the brain. Meanwhile, anti-apoptotic factors in the implanted cells could bolster cell survival after implantation.

Even though there is a great deal known about the reparative microenvironment of injured peripheral nerves in animal models, data on human peripheral nerve repair and its neuroprotective properties are sparse. To fill this gap in knowledge, we collected human peripheral (sural) nerve tissue before and after transection injury (herein referred to as naïve and reparative for consistency). We used single nuclei RNA sequencing (RNA seq) and immunoassays to generate a profile of the cell types, the RNA expression, and protein content of key neuroprotective factors present in reparative peripheral nerve tissue. The objective of this study is to report our findings of the specific cell types and contents of the reparative human nerve. Our results focus primarily on the properties and contents of the reparative tissue as this is the final product implanted into the brain. This information will provide insight on this tissue’s utility as a neuroprotective cell therapy.

**Methods**

**Research Participants**

The collection of peripheral nerve tissue was approved as part of a more expansive clinical trial that received approval from the University of Kentucky’s Institutional Review Board and was registered at clinicaltrials.gov (NCT02369003). The participants provided written informed consent. Peripheral nerve tissue of the sural nerve was collected from 15 participants before and after sural nerve transection in situ for immunoassay studies. The range of differences between naïve and reparative tissue has been previously published by Chau et al. Sural nerve tissue was collected from two additional participants for single nuclei RNA seq studies.

Peripheral nerve tissue samples were collected from 15 participants for immunoassays (mean: 60 years old, range: 51–69 years, assigned birth sex: 9 male/6 female, years since PD diagnosis mean: 10 years, range: 4–17 years). Samples were collected from two additional participants for single nuclei RNA seq (ages were 49 and 60 years old, assigned birth sex: both male, years diagnosed with PD: 7 and 5 years). The time between transection of the nerve (naïve) and collection of regenerating peripheral nerve tissue was 12 and 17 days for participants 1 and 2, respectively.

**Peripheral Nerve Transection and Tissue Collection**

Transection of the peripheral nerve and the tissue collection has been previously described. Fig. 1 illustrates the naïve and transection injury–induced sural nerve collection approximately 2 weeks after transection. Conventionally, naïve nerve tissue is defined as tissue that had not degenerated. Our naïve tissue had been transected (and flash-frozen after) to remove it from the body, so it is not completely uninjured. However, for the purposes of this study and ease of understanding, we will call this “naïve” tissue at 0 days relative to the “reparative” tissue at approximately 2 weeks.

Briefly, the neurosurgeon identified the neurovascular bundle containing the sural nerve in the ankle and transected it and removed 1 to 2 cm of nerve of naïve tissue (Fig. 1). The nerve tissue was cleaned of loosely external tissues (fat tissue, blood vessels), and individual nerve fascicles (usually 6–10 per patient) were separated manually. The fascicles were cleaned of adherent connective tissue and snap-frozen in centrifuge tubes on crushed dry ice. The fascicles were
Chau et al

stored in a −80 Freezer for analysis by immunoassays (as in Welleford et al.)13. Approximately 2 weeks later, for both analysis and implantation into the substantia nigra for the clinical trial (Fig. 1), the ankle incision was reopened and 1 to 2 cm of the injured peripheral nerve tissue was excised from the distal nerve stump. The individual nerve fascicles were separated, snap-frozen, and stored for assays as described above for the naïve tissue13. Transection-injured tissue collection time from dissection to snap-freezing was 32 min for one participant, and 67 min for the other participant. These frozen samples of nerve fascicles were used in single nuclei RNA seq and immunoassays (weight per sample ranged from 40 to 170 mg).

Histology

Reparative peripheral nerve was stained with hematoxylin and eosin (H&E) and MCOLL staining. MCOLL staining distinguishes myelin, collagen fibers, and cells in the peripheral nerve30. The nerve was placed in 4% paraformaldehyde solution, then embedded in paraffin blocks for histology 31. Sections were all taken from within approximately 1 mm from the end of each nerve (as the sections were cut from the terminal end).

Single Nuclei RNA Seq

Single nuclei RNA seq and analysis were conducted by Singulomics Corporation (https://singulomics.com, Bronx, NY). In summary, frozen sural nerve fascicles (1–2 cm each) were homogenized and lysed with Triton X-100 in RNase-free water for nuclei isolation. The isolated nuclei were purified, centrifuged, and resuspended in phosphate buffered saline (PBS) with bovine serum albumin (BSA) and ribonuclease (RNase) Inhibitor. The nuclei were diluted to 700 nuclei/ul and loaded to 10x Genomics Chromium Controller to encapsulate single nuclei into droplet emulsions following the manufacturer’s recommendations (Pleasanton, CA, USA). Library preparation was performed according to the instructions in the Chromium Next GEM 3' Single Cell Reagent kits v3.1. Amplified cDNAs and the libraries were measured by Qubit dsDNA HS assay (Thermo Fisher Scientific, Wilmington, DE, USA) and quality assessed by BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). Libraries were sequenced on a NovaSeq 6000 instrument (Illumina, San Diego, CA, USA), and reads were subsequently processed using 10x Genomics Chromium Controller v5.0.1 and human GRCh38 reference genome with introns included in the analysis. Dataset aggregation was performed using the cellranger aggr function normalizing for the total number of confidently mapped reads across libraries.

Seurat 4.0.1 was used to further clean and normalize the data. The data from barcodes with mitochondrial genes at a level of <5% of total gene counts and with a minimum of 1400 UMI counts were retained. Gene read counts were normalized with the Seurat “NormalizeData” function. The top 3000 highly variable genes were identified using Seurat “FindVariableFeatures” function, which were used for principal components analysis (PCA) using Seurat “RunPCA”
function. Clustering was done using Seurat “FindClusters” function based on 11 PCAs. The ElbowPlot test was done to determine the number of PCAs used. Visualization of the cells was performed using the Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) algorithm as implemented by the Seurat “runUMAP” function. Violin plots were graphed as a log2 fold average count for RNA expression in each defined cell cluster through C Loupe 5.0 software (10x Genomics).

**Immunohistochemistry and Imaging**

Transcriptionally Distinctive Cell Types

Reparative Peripheral Nerve Tissue Contains Transcriptionally Distinctive Cell Types

Results

We used single nuclei RNA seq to identify the cell types present in reparative peripheral nerve tissue based on transcriptional profiling (Fig. 2A). Single nuclei RNA seq data from two participants were aggregated (Fig. 2A). Cell clustering by cell type was reproducible across both participants (Fig. 2B). The data clustered into 10 cell groups and were defined based on characteristic genes in previously published single cell data for each particular cell type (Fig. 2C)\(^{22-41}\). Cell counts were obtained from the single nuclei RNA seq analysis and each cluster’s percentage was reported (Fig. 2D). An output of 2425 cells and 2643 cells were used from both participants.

Cell clusters observed included typical Schwann cells (defined by their expression of *S100B, ERBB3*, and other lineage-specific genes), macrophages (*ITGAM*), T-cells (*CDNF*), endothelial cells (*PECAM1*), and pericytes (*ACTA2*) (Fig. 2C). The content of mature (myelinating) Schwann cells was negligible (0.2%). The small number of (myelinating) Schwann cells was an expected finding considering that the nerve transection had a removal of the intermediate segment. The proximal and distal stumps could not physically reconnect, thus could not form axonal regeneration. A proportion of Schwann cells, macrophages, endothelial cells, and T-cells exhibited expression of genes associated with active cell division (Fig. 2A, B, red clusters). The distribution of proliferative cells was coincidentally conserved in the two donors (Fig. 2B).

Different than what we had expected, a large proportion of the cells were mesenchymal cells including a cluster of mesenchymal cells expressing stem cell–associated genes (*TWIST1*\(^{37}\), *PDGFR\(^{47}\)*, and *ADAM12*) and endoneurial mesenchymal cells (Fig. 2C, D). These endoneurial mesenchymal cells were defined by *ETV1*\(^{32,40}\) and *OSR2*\(^{33,40,41}\), and were positive for the mesenchymal marker, *PDGFR\(^{A}\)* (Fig. 2C). Another unexpected result was that one cell cluster contained a heterogeneous mix of cells including perineurial cells with the expression of markers *SLC2A1*\(^{42}\) and *LMO7*\(^{42}\), and possibly repair Schwann cells (*NGFR*)\(^{37}\).

**Reparative Peripheral Nerve Tissue Shows RNA Expression of Neuroprotective Factors 2 Weeks After Nerve Transection**

In this study, we aimed to identify a select group of neuroprotective factors in the regenerating tissue and localize the RNA expression to specific cell types (Fig. 3). This differs from our previous work in the whole nerve tissue in which Welleford et al. had identified gene expression of neuroprotective and anti-apoptotic factor pathways\(^{13}\). UMAP plots illustrate the cell-type expression of the neuroprotective factors of interest: *BDNF, EPO, CDNF, GDNF, NGF, PDGF, PDGFB, and VEGFA* (Fig. 3A). The accompanying violin plots show the relative RNA expression level (log2 average) and frequencies for each cell type in the regenerating peripheral nerve tissue (Fig. 3A).

Even though certain factors (*GDNF, CDNF, EPO*) did not show much RNA expression, we included these data as we compared them with their protein level expression. Repair Schwann cells are a source of neuroprotective factor release
Regenerating Tissue Cell Types
Participant data aggregated

A
Myelinating Schwann cells
Schwann cells
Endoneurial mesenchymal cells
Macrophages
Pericytes, VMSCs
Proliferating cells
T-cell
Heterogeneous cells
Mesenchymal cells

B
Participant 1
Participant 2

| CELL TYPE                   | DEFINING GENES                                                                 |
|-----------------------------|-------------------------------------------------------------------------------|
| Schwann cells               | S100B, ERBB3, NCAM1, SOX10, PLP1                                              |
| Myelinating Schwann cells   | MBP, MPZ, NCMAP                                                                |
| Endothelial cells           | VWF, EGF, TPO, PLVAP, PDGFB, PECAM1, CLDN5, ECMR                              |
| Proliferating cells         | MKI67, TOP2A, FOXM1                                                            |
| Heterogeneous cells (including Perineurial cells) | Perineurial: SLC2A1, LMO7, NGFR-positive cells present |
| Endoneurial mesenchymal cells | ETV1, OSR2, PDGFR-A-positive cells present                                   |
| Mesenchymal cells           | PDGFR-A, ADAM12, TWIST1                                                        |
| Macrophages                 | SIGLEC1, TFR/CD71, ITGAM/CD11b                                                |
| Pericytes/vascular smooth muscle cells | TPM2, ACTA2, PDGFRB                                                        |
| T-cell                      | SKAP1, THEMIS, IL7R                                                            |

D
Pericytes, Vascular Smooth Muscle Cells (5.2%)
Schwann Cells (5.7%)
Myelinating Schwann Cells (0.2%)
Macrophages (4.2%)
Endothelial Cells (24.0%)
Mesenchymal Cells (17.2%)
Endoneurial Mesenchymal Cells (11.6%)
Heterogeneous Cells (14.9%)

Figure 2. Reparative peripheral nerve tissue contains several cell types including regenerating cells. (A) Aggregate of single nuclei RNA sequencing from two participants. Ten unique cell type clusters were present in the reparative tissue. (B) Data from two participants show similarity in their cellular profiles. (C) The data clustered into 10 cell groups and were defined based on characteristic genes previously published for each particular cell type. (D) Each cell cluster’s percentage of total number of cells is reported.
Figure 3. Reparative peripheral nerve tissue shows RNA expression of neuroprotective factors 2 weeks after nerve transection. (A) Single nuclei RNA sequencing UMAP plots show cell-type expression of the neuroprotective factors of interest: NGF, PDGFB, VEGFA, PDGFA, CDNF, GDNF, BDNF, and EPO. The accompanying violin plots show the relative RNA expression level (log2 average) and frequencies for each cell type in the reparative peripheral nerve tissue. NGF, PDGFA, PDGFB, and VEGF were localized to more than one cell type. NGF was localized to the heterogeneous cell cluster and endoneurial mesenchymal cells; NGFR was localized to Schwann cells and the heterogeneous cell cluster; PDGFA was localized to myelinating Schwann cells and pericytes/vascular smooth muscle cells; PDGFB was highly expressed in endothelial cells. Cell type key: SC: Schwann cell; mySC: myelinating Schwann cells; EC: endothelial cells; PC: proliferating cells; HC: heterogeneous cells; EMC: endoneurial mesenchymal cells; MC: mesenchymal cells; M: macrophages; PC/VMSC: pericytes/vascular smooth muscle cells; TC: T-cells. (B) Repair Schwann cells are a source of neuroprotective factor release. NGFR is an abundantly expressed repair Schwann cell marker that was found in the Schwann and heterogeneous cell clusters. (C) Percentage of
in reparative nerve. We included the most abundant repair Schwann cell marker expressed in the tissue, NGFR\textsuperscript{37} to understand the relative location and presence of repair Schwann cells in the tissue (Fig. 3B).

Factors such as NGF, PDGFA, PDGFB, and VEGFA were localized to more than one cell type (Fig. 3A, violin plots). NGF was localized to the heterogeneous cells cluster and endoneurial mesenchymal cell cluster, PDGFA was localized to myelinating Schwann cells and pericytes/vascular smooth muscle cells, PDGFB was highly expressed in endothelial cells and proliferating cells. Among the key neuroprotective factors, NGF (15.2% of cells) and PDGFB (10.9% of cells) were the most widely expressed factors (RNA) across cells of the reparative nerve tissue while GDNF (0.8%), BDNF (0.3%), and EPO (0.04%) were the most limited in expression (Fig. 3B). NGFR was expressed in 13.5% of cells (Fig. 3B, note that the x-axis maximum is 20%).

Reparative Peripheral Nerve Tissue Shows RNA Expression of Anti-Apoptotic Factors Across Multiple Cell Types

The anti-apoptotic factors, NFE2L2 (NRF2), BCL2, BCL2L1 (Bcl-xl), and MCL1 were expressed broadly and robustly in many of the cell types. Violin plots show the relative expression across cell types (log2 average) (Fig. 4A). Among the anti-apoptosis factors, NFE2L2 (36.3% of cells) and BCL2 (28.6% of cells) were the most widely expressed factors across cells of the reparative peripheral nerve tissue while BCL6 (16.9%) and MCL1 (14.5%) were the most limited in expression (Fig. 4B, note that the x-axis maximum is 40%).

Protein Content of Neuroprotective Factors and Anti-Apoptotic Factors

To measure the protein content of neuroprotective and anti-apoptotic factors in reparative peripheral nerve tissue, we conducted immunoassays for several proteins we had characterized with single nuclei RNA seq (Figs. 2–4). The mean protein concentration (and SD) in reparative peripheral nerve tissue samples is summarized in Fig. 5.

Discussion

In this report, we focused on the final product that is implanted into the brain in our clinical trial, the reparative peripheral nerve. We identified the cell types in the peripheral nerve tissue that is used for implantation. Furthermore, this work details the distribution of neuroprotective and anti-apoptotic factors within these cell types, and their protein concentrations. In animal models, multiple cell types contribute to peripheral nerve repair, notably repair Schwann cells\textsuperscript{13–46}, endothelial cells, and immune cells such as macrophages\textsuperscript{37–49}. In the two single nuclei RNA seq subjects with PD in this study, the major cell types in reparative human peripheral nerve tissue were consistent and reproducible (Fig. 2). Understanding the contents of this investigational cell therapy is a critical step in optimizing the product’s survival and its ability to neuroprotect vulnerable neurons. We collected samples from same-subject in situ peripheral nerve degeneration. It is not typically feasible to collect tissues before an injury has occurred\textsuperscript{46}; thus, this type of information has not been available in humans before.

Actively Regenerating Nerve Tissue Serves as a Vehicle for Neuroprotective Factors

In this study, we show a clear upregulation of neuroprotective factors. Interestingly, the results showed low mRNA expression for certain neuroprotective factors including BDNF, GDNF, VEGF, but the protein content was highly expressed. Low mRNA expression but high protein expression may mean that the mRNA was already translated into protein at this time point.

To provide the putative beneficial factors found in reparative peripheral nerve tissue requires the delivery of the collective content of peripheral nerve tissue and not a single cell-type in isolation\textsuperscript{51,52}. The combination of cell types has the benefit of including all of the neuroprotective, growth, pro-regenerative, cell survival factors, and anti-inflammatory factors, available from living reparative nerve tissue to support of degenerating cells in the central nervous system (CNS)\textsuperscript{13,15} (Fig. 6).

The reparative human peripheral nerve is living tissue, as it is freshly dissected from the participant’s ankle and immediately implanted into the brain (Fig. 1). For how long the neuroprotection continues after implantation remains unclear. We speculate that there is a persistent delivery of these factors up to a point to support degenerating cells. In previous reports of participants that had received this implantation in preliminary, open-label trials, we observed an improvement in Unified Parkinson’s Disease Rating Scale (UPDRS) part III motors scores at 12 months\textsuperscript{9,53}. Furthermore,
in unpublished results from our group, post-mortem sections of a participant who had been engrafted with reparative peripheral nerve tissue to the midbrain 33 months earlier showed immunoreactivity to NGFR present in the area around the engraftment. This suggests the presence of Schwann-like glia or repair Schwann cells which could be a source of neuroprotective factor release and repair. Future studies should be designed to measure secretion levels from reparative peripheral nerve tissue to analyze this tissue beyond the implantation site.

Even though the anti-apoptotic factors that we highlight in this study are not secreted, their robust expression in the transplanted cells could bolster their own survival after implantation. It is typical to find high levels of anti-apoptotic genes in transected nerves in all cell types. These cells are primed for survival and reprogramming due to the transection. We used this to our advantage to implant a robust product. A percentage of transplanted neural stem cells die due to the trauma and manipulation of cells days after transplantation into the brain. This suggests that cell survival may be supported by a robust expression of anti-apoptotic factors in the implanted cells. In addition, neurotrophic factors are also inherently anti-apoptotic and pro-survival.

**Beneficial Cell Types in Active Reparative Tissue**

*Repair Schwann cells.* Much of the work surrounding the reparative cell types in peripheral nerve tissue focuses on repair Schwann cells. After injury or transection, Schwann cells undergo an extensive reprogramming that transforms the mature myelinating and non-myelinating (Remak) cells into dedifferentiated, repair cells. Repair Schwann cells release neuroprotective factors to facilitate axonal regeneration. In the early phase of the response to injury, Schwann cells undergo an epithelial-mesenchymal...
transition (EMT)-like process with the upregulation in the expression of stem cell–associated transcription factors such as Sox2, Notch1, and Oct6. This EMT-like process transforms cells to be similar to multipotent stem cells and release neurotrophic factors and support cell survival. In animal models, transplanted Schwann cells have been shown to provide support to dopaminergic cells in vivo.

To contextualize this to our single nuclei RNA seq analysis, the data segregated into a very small population of myelinating Schwann cells (0.2%, Fig. 2) and a larger population of non-myelinating Schwann cells (5.7%). These clusters shown represent the “typical” Schwann cells based on classic marker expression (MBP, MPZ, S100B, ERBB3, NCAM1, and SOX10). We expected the myelinating Schwann cell population to be small as this phenotype is consistently downregulated after transection. Likely, the myelinating and non-myelinating Schwann cells transformed into repair cells after transection. However, our data suggest that repair Schwann cells may be more heterogeneous and widespread in different clusters than the clearly defined Schwann cell clusters shown.

Many clusters beyond the defined Schwann cell clusters may contain repair Schwann cells including the heterogeneous, mesenchymal, and epineurial mesenchymal cell clusters. We observed in these clusters the expression of NGFR (a marker for Schwann-like glia cells) that may represent the presence of repair Schwann cells. The heterogeneous cell cluster in our analysis shows the most NGFR-positivity only second to the non-myelinating Schwann cell cluster; thus, we have interpreted that this cluster may contain repair Schwann cells. We have named this as a heterogeneous cluster due to the presence of other cell types such as perineurial cells and mesenchymal cells (Fig. 2C). Further histology would be needed to confirm the phenotypes.

As for other markers that typically characterize repair Schwann cells, they were present in the Schwann and in the heterogeneous cell clusters, but do not segregate as their own defined cluster in the UMAP plot. These markers are NCAM1, NGFR, and SOX2 for immature Schwann cells. Mature Schwann cells de-differentiate into a flexible phenotype after injury. Other markers of repair Schwann cells

| Protein      | Reparative Nerve Protein Content mean (SD) |
|--------------|------------------------------------------|
| BDNF         | 8.0 (7.7) pg/ml                          |
| CDNF         | 173.7 (98.6) pg/ml                       |
| EPO          | 321.6 (148.2) pg/ml                      |
| GDNF         | 53.2 (36.1) pg/ml                        |
| beta-NGF     | 42.5 (51.3) pg/ml                        |
| NGFR         | 300 (200) pg/ml                          |
| PDGF-AA      | 4.9 (3.0) pg/ml                          |
| PDGF-BB      | 3.7 (2.7) pg/ml                          |
| VEGF         | 6.9 (5.0) pg/ml                          |
| NFE2L2       | 61.2 (22.0) pg/ml                        |
| BCL6         | 1200 (600) pg/ml                         |

Figure 5. Protein content of neuroprotective factors and anti-apoptotic factors. The mean protein concentration (and SD) in regenerating peripheral nerve tissue samples is summarized. BDNF (n = 15 participant samples), GDNF (n = 7), beta-NGF (n = 12), PDGF (n = 15), VEGF (n = 15), NGFR (n = 14), CDNF (n = 15), PDGFA (n = 13), EPO (n = 13), NFE2L2 (n = 14), and BCL-6 (n = 15). BDNF: brain-derived neurotrophic factor; CDNF: cerebral dopamine neurotrophic factor; EPO: erythropoietin; GDNF: glial-cell derived neurotrophic factor; NGF: nerve growth factor; NGFR: nerve growth factor receptor; PDGFA: platelet-derived growth factor–A; PDGF: platelet-derived growth factor–B; VEGF: vascular endothelial growth factor.

Figure 6. Proposed action of reparative peripheral nerve tissue transplant. Reparative peripheral nerve tissue deployed into the substantia nigra of participants with PD may act in multi-factorial ways with paracrine effects on the surrounding tissue. Anti-apoptotic factors may contribute to graft survival. Through this combination, a diversity of cell-types from regenerating peripheral nerve tissue could provide neuroprotective, pro-regenerative, and anti-inflammatory factors interacting with the degenerating cells in the CNS. Created with Biorender.com. CNS: central nervous system; PD: Parkinson’s disease.
expressed in our reparative peripheral nerve tissue were EGR2 and SHH, but the presence of these markers were not very high in the tissue. We had expected that Schwann cells would be a bigger proportion of cells in our results\textsuperscript{19}. The lower Schwann cell count could be explained by the mature Schwann cells having already de-differentiated into a mesenchymal cell type at 2 weeks.

The connection between mesenchymal cells and Schwann cells should not be overlooked. Clements et al. revealed novel aspects of Schwann cell de-differentiation after nerve transection including the transformation into a mesenchymal phenotype\textsuperscript{36}. They found that transforming growth factor (TGF)-beta reprograms the bridge Schwann cells involved in reconnecting the axon into mesenchymal-like cells and a migratory phenotype to drive cells across the wound\textsuperscript{36}. Our data revealed sizable mesenchymal cell populations (mesenchymal cluster, endoneurial mesenchymal cluster) possibly due to the de-differentiation of Schwann cells after transection. Furthermore, a marker for mesenchymal cells, PDGFR\textalpha in our data was also found in other clusters like the heterogeneous cell cluster suggesting that mesenchymal cells may exist beyond just the clearly defined mesenchymal/epineurial mesenchymal clusters.

**Macrophages as reparative and anti-inflammatory.** Our data show that macrophages were 12.2\% of the total cells 2 weeks after transection, and the fourth largest cluster of cells after transection. Macrophages play dichotomous roles in injury in pro-inflammatory (M1) and anti-inflammatory (M2) ways. M1 macrophages are pro-inflammatory and secrete cytokines, and M2 macrophages are anti-inflammatory and contribute to tissue repair\textsuperscript{60}. The switch in the polarization of their phenotype is influenced by their environment. The dual roles of macrophages allow them to contribute in tissue homeostasis such as in injury progression and also tissue repair. Soon after injury, macrophages also play an important role in engulfing myelin and axonal debris\textsuperscript{60}. M1 pro-inflammatory macrophages release chemokine ligand 2 (CCL2), inducible nitric oxide synthase, and tumor necrosis factor (TNF)-related apoptosis-inducing ligand. M1 macrophages promote the removal of debris and clearing of apoptotic cells\textsuperscript{61}. The many subtypes of M2 macrophages induce anti-inflammatory effects to promote the resolution of inflammation, cell proliferation, growth factor production, tissue repair, angiogenesis, and wound healing\textsuperscript{61–63}. Our data did not segregate into M1 and M2 phenotypes; however, transplanting the macrophages in the M2 phenotype could be beneficial to degenerating neurons contributing to tissue repair\textsuperscript{61–63}.

**Data Interpretation**

Even as a powerful tool, there are limitations to the single nuclei RNA seq approach\textsuperscript{64}. The clusters of cells are generated via automatic bioinformatics analysis and may or may not reveal all the actual cell types as evidenced by anatomical location, function, or immunochemistry. One of the clusters exhibited the heterogeneity of several cell types including perineurial cells, markers for Schwann cells, and mesenchymal cells. More specific histology staining for the characteristic markers of these cell is needed to confirm cell identities.

One concern from our previous whole tissue RNA seq analysis\textsuperscript{13} had been the time between excision and freezing of the tissue; but in later proteomic analyses, differences in sample freezing times did not appear to account for proteomic differences\textsuperscript{15}. Meanwhile, in the two participants whose peripheral nerve tissue underwent single nuclei RNA seq analysis, the UMAP display of cell clusters were concordant even though there was a greater than 30-min difference (67 vs 32 min) in freezing times for peripheral nerve tissue between participants. Our interpretation is that the profile of the regenerating peripheral nerve tissue is stable under our collection conditions. We recognize that ideally, the freezing time should be reduced further to more definitively maintain the stability of the samples, but based on the current design of the trial and surgery logistics, a shorter freezing time is not practically possible. Furthermore, the timing of sample collection of reparative peripheral nerve tissue is the actual timing for the peripheral nerve tissue that is implanted in clinical trials, and we detected and measured the concentration of key factors in this product (Fig. 5).

In previous studies\textsuperscript{65–67} where embryonic stem cells or embryonic dopaminergic neurons were transplanted into the basal ganglia of participants with PD, the number of cells transplanted has varied across studies, sometimes limited by the availability of embryos and stem cells. That variability has been wide, from transplanting into the putamen 20 µl of embryonic mesencephalic tissue containing dopamine neurons from fragments of aborted embryos\textsuperscript{2}, to 9861 to 21,552 embryonic dopaminergic neurons per putamen side\textsuperscript{68}, to dopaminergic neurons from one or four donor embryos per side (approximately 30,000 cells per side for one embryo and 70,000–120,000 cells per side from four embryos). Based on the cell counts reported here, we estimate the delivery of 5000 to 10,000 cells of reparative peripheral nerve tissue per deployment, of course with a different cell composition, and objective, from dopaminergic transplants.

We recognize the use of tissue from participants with PD introduces a concern of neuropathies as people with PD have a higher incidence\textsuperscript{69,70}. For the single nuclei RNA seq, one of the participants had no history of neuropathy, and one did have a history of neuropathy. Even with these limitations, this study provides insight into the composition of the reparative peripheral nerve tissue implanted in ongoing clinical trials.

**Summary**

In this work, we were able to demonstrate the types of cells and the anti-apoptotic and neuroprotective contents that are implanted into our trial participants. This novel reparative
peripheral nerve tissue engraftment may also have immediate utility in other neurodegenerative diseases such as stroke\textsuperscript{71–73}, traumatic brain injury (TBI), and Alzheimer’s disease. We found that multiple cell types in reparative peripheral nerve tissue contribute to the production of a wide array of factors utilized in our goal to alter the progression of PD.

Acknowledgments
We acknowledge the assistance of the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children’s Hospital Medical Center and Alyssa Sproles. We thank Morgan Yazell for trial execution, Tom Dolan for medical illustration, Dr Jeremiah Smith for assistance on 10x single cell analysis. Thank you to Drs Joyce Peng and Noel Chen of Singulomics Corporation. Nuclei isolation, single nucleus RNA sequencing, and analysis were conducted by Singulomics Corporation (https://singulomics.com/, Bronx NY).

Ethical approval and consent to participate
The University of Kentucky’s Institutional Review Board (IRB) approved the study (clinicaltrials.gov: NCT02369003), and the participants provided written informed consent.

Statement of Human and Animal Rights
This article does not contain any studies on animal subjects.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by University of Kentucky Neuroscience Research Priority Area Award, University of Kentucky College of Medicine BRAIN Alliance grant, Ann Hanley Parkinson’s Research Fund, and the National Center for Advancing Translational Sciences, through NIH grant UL1TR001998. P.V.M. received support from the Indiana State Department of Health (grants 33997 and 43547).

ORCID iDs
Monica J. Chau \[https://orcid.org/0000-0001-8858-9937\]
Jorge E. Quintero \[https://orcid.org/0000-0003-3088-7565\]
Andrew S. Welleford \[https://orcid.org/0000-0001-5965-4998\]

References
1. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54(3):403–14.
2. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowsk JQ, Eidelberg D, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344(10):710–19.
3. Wider C, Pollo C, Bloch J, Burkhard PR, Vingerhoets FJ. Long-term outcome of 50 consecutive Parkinson’s disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord. 2008;14(2):114–19.
4. Barker RA, TRANSEURO consortium. Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease. Nat Med. 2019;25(7):1045–53.
5. Takahashi J. Preparing for first human trial of induced pluripotent stem cell-derived cells for Parkinson’s disease: an interview with Jun Takahashi. Regen Med. 2019;14(2):93–95.
6. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiu M, Ideno H, Shimada A, Nifuj A, Abe M. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013;494(7435):100–104.
7. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212–15.
8. van Horne CG, Quintero JE, Gurwell JA, Wagner RP, Slevin JT, Gerhardt GA. Implantation of autologous peripheral nerve grafts into the substantia Nigra of subjects with idiopathic Parkinson’s disease treated with bilateral STN DBS: a report of safety and feasibility. J Neurosurg. 2017;126(4):1140–47.
9. van Horne CG, Quintero JE, Slevin JT, Anderson-Mooney A, Gurwell JA, Welleford AS, Lamm JR, Wagner RP, Gerhardt GA. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018;129(6):1550–61.
10. Weiss T, Taschner-Mandl S, Bileck A, Slany A, Kromp F, Rifatbegovic F, Frech C, Windhager R, Kitzinger H, Tzou CH, Ambros PF, et al. Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype. Glia. 2016;64(12):2133–53.
11. Steriell S, Napoli I, White JI, Cattin AL, Montezza Cabrejos A, Garcia Calavia N, Malong L, Ribeiro S, Nihouarn J, Williams R, Young KM, et al. The regulation of the homeostasis and regeneration of peripheral nerve is distinct from the CNS and independent of a stem cell population. Development. 2018;145(24):dev170316.
12. Gordon T. Peripheral nerve regeneration and muscle reinnervation. Int J Mol Sci. 2020;21(22):8652.
13. Welleford AS, Quintero JE, Sebiani NE, Blalock E, Gunewardena S, Shapiro SM, Riordan SM, Huettl P, Guduru Z, Stanford JA, van Horne CG, et al. RNA sequencing of human peripheral nerve in response to injury: distinctive analysis of the nerve repair pathways. Cell Transplant. 2020;29:963687920926157.
14. Acheson A, Conover JC, Fandl JP, DeChiara TM, Russell M, Thadani A, Squinto SP, Yancopoulos GD, Lindsay RM. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature. 1995;374(6521):450–53.
15. Chau MJ, Quintero JE, Blalock E, Samaan C, Gerhardt G, van Horne C. Transaction injury differentially alters the proteome of the human sural nerve. Biowriv. 2021:2021;20211123469670.
16. Meyer M, Matsuoka I, Wetmore C, Olson L, Thoenen H. Enhanced synthesis of brain-derived neurotrophic factor in the lesioned peripheral nerve: different mechanisms are responsible for the regulation of BDNF and NGF mRNA. J Cell Biol. 1992;119(1):45–54.

17. Hilton DA, Jacob J, Househam L, Tengah C. Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry. 2007;78(11):1271–72.

18. Campbell CA, Turza KC, Morgan RF. Postoperative outcomes and reliability of “sensation-sparing” sural nerve biopsy. Muscle Nerve. 2009;40(4):603–609.

19. Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589–95.

20. Nutter JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(6):69–73.

21. Collier TJ, Elsworth JD, Taylor JR, Sladek JR Jr, Roth RH, Redmond DE Jr. Peripheral nerve-dopamine neuron co-grafts line-derived neurotrophic factor in PD. J Neurosurg. 2004;101(3):11839–44.

22. Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, et al. Randomized trial of intermittent intratramenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain. 2019;142(3):512–25.

23. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 2013;80(18):1698–1701.

24. Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, et al. Randomized trial of intermittent intratramenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain. 2019;142(3):512–25.

25. Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol. 2015;78(2):248–57.

26. Park KI. Transplantation of neural stem cells: cellular & gene therapy for hypoxic-ischemic brain injury. Yonsei Med J. 2000;41(6):825–35.

27. Ishibashi S, Sakaguchi M, Kuroiwa T, Yamashita K, Kanemura Y, Shirako K, Shimazaki T, Onodera M, Okano H, Mizusawa H. Human neural stem/progenitor cells, expanded and reprogrammed to drive peripheral nerve regeneration. Front Cell Neurosci. 2021;15:624826.

28. Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC, Masel J, Yenari MA, Weissman IL, Uchida N, Palmer T, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A. 2004;101(32):11839–44.

29. Carrington EM, Zhan Y, Brady JL, Zhang JG, Sutherland RM, Anstee NS, Schenk RL, Vikstrom IB, Delconte RB, Segal D, Huntingdon ND, et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ. 2017;24(5):878–88.

30. Carriere V, Garzon I, Alaminos M, Campos A. Evaluation of myelin sheath and collagen reorganization pattern in a model of peripheral nerve regeneration using an integrated histochemical approach. Histochem Cell Biol. 2011;136(6):709–17.

31. Raimondo S, Fornaro M, Di Scipio F, Ronchi G, Giacobini-Robecchi MG, Geuna S. Chapter 5: methods and protocols in peripheral nerve regeneration experimental research: part II—morphological techniques. Int Rev Neurobiol. 2009;87:81–103.

32. Carr MJ, Toma JS, Johnston APW, Steadman PE, Yuzwa SA, Mahmud N, Frankland PW, Kaplan DR, Miller FD. Mesenchymal precursor cells in adult nerves contribute to mammalian tissue repair and regeneration. Cell Stem Cell. 2019;24(2):240.e9–56.

33. Chen B, Banton MC, Singh L, Parkinson DB, Dun XP. Single cell transcriptome data analysis defines the heterogeneity of peripheral nerve cells in homeostasis and regeneration. Front Cell Neurosci. 2021;15:624826.

34. Li M, Min Q, Banton MC, Dun X. Single-cell regulatory network inference and clustering identifies cell-type specific expression pattern of transcription factors in mouse sciatic nerve. Front Cell Neurosci. 2021;15:676515.

35. Richard L, Vedrenne N, Vallat JM, Funalot B. Characterization of endoneurial fibroblast-like cells from human and rat peripheral nerves. J Histochem Cytochem. 2014;62(6):424–35.

36. Clements MP, Byrne E, Camarillo Guerrero LF, Cattin AL, Zakka L, Ashraf A, Burden JJ, Khadayate S, Lloyd AC, Marguerat S, Parrinello S. The wound microenvironment reprograms Schwann cells to invasive mesenchymal-like cells to drive peripheral nerve regeneration. Neuron. 2017;96(1):e7–14.

37. Peng K, Sant D, Andersen N, Silvera R, Camarena V, Piner O, Graham R, Khan A, Xu XM, Wang G, Monje PV. Magnetic separation of peripheral nerve-resident cells underscores key molecular features of human Schwann cells and fibroblasts: an immunological and transcriptomics approach. Sci Rep. 2020;10(1):18433.

38. Wei Z, Shu S, Zhang M, Xie S, Tang S, Nie K, Li H. A subpopulation of Schwann cell-like cells with nerve regeneration signatures is identified through single-cell RNA sequencing. Front Cell Neurosci. 2021;12:637924.

39. Gerber D, Pereira JA, Gerber J, Tan G, Dimitrieva S, Yanguel E, Suter U. Transcriptional profiling of mouse peripheral nerves to the single-cell level to build a sciatic nerve ATlas (SNAT). Elife. 2021;10:e58591.

40. Toma JS, Karamboulas K, Carr MJ, Kolaj A, Yuzwa SA, Mahmud N, Storer MA, Kaplan DR, Miller FD. Peripheral nerve single-cell analysis identifies mesenchymal ligands that promote axonal growth. Eureo. 2020;7(3):2020.

41. Wolbert J, Li X, Heming M, Mausberg AK, Akkermann D, Frydrychowicz C, Fledrich R, Groeneweg L, Schulz C, Stettner M, Gonzalez NA, et al. Redefining the heterogeneity of peripheral nerve cells in health and autoimmune. Proc Natl Acad Sci U S A. 2020;117(17):9466–76.

42. Miller BA, Turan N, Chau M, Pradilla G. Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage. Biomed Res Int. 2014;2014:384342.
phase and its relation to nerve fibre degeneration. J Neurocytol. 1986;15(1):17–28.

44. Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Banerjee A, Woodhoo A, Jenkins B, Rahman M, Turmaine M, Wicher GK, et al. c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron. 2012;75(4):633–47.

45. Fontana X, Hristova M, Da Costa C, Patodia S, Thei L, Mkwana M, Spencer-Dene B, Latouche M, Mirsky R, Jessen KR, Klein R, et al. c-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling. J Cell Biol. 2012;198(1):127–41.

46. Jessen KR, Mirsky R. The repair Schwann cell and its function in regenerating nerves. J Physiol. 2016;594(13):3521–31.

47. La Fleur M, Underwood JL, Rappolee DA, Werb Z. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J Exp Med. 1996;184(6):2311–26.

48. Mueller M, Leonhard C, Wacker K, Ringelstein EB, Okabe M, Hickey WF, Kiefer R. Macrophage response to peripheral nerve injury: the quantitative contribution of resident and hematogenous macrophages. Lab Invest. 2003;83(2):175–85.

49. Stratton JA, Holmes A, Rosin NL, Sinha S, Vohra M, Burma NE, Trang T, Midha R, Biernaskie J. Macrophages regulate Schwann cell maturation after nerve injury. Cell Rep. 2018;24(10):2561.e6–72.e6.

50. Wilcox MB, Laranjeira SG, Eriksson TM, Jessen KR, Mirsky R, Quick TJ, Phillips JB. Characterising cellular and molecular features of human peripheral nerve degeneration. Acta Neuropathol Commun. 2020;8(1):51.

51. Anderson KD, Guest JD, Dietrich WD, Bartlett Bunge M, Curiel R, Dididze M, Green BA, Khan A, Pearse DD, Saraf-Lavi E, Widerström-Noga E. Safety of autologous human Schwann cell transplantation in subacute thoracic spinal cord injury. J Neurotrauma. 2017;34(21):2950–63.

52. Xia Y, Jiang C, Cao Z, Shi K, Wang Y. Co-transplantation of macaque autologous Schwann cells and human embryonic nerve stem cells in treatment of macaque Parkinson’s disease. Asian Pac J Trop Med. 2012;5(1):7–14.

53. Quintero JE, Slevin JT, Gurwell JA, McLouth CJ, Khoulie RE, Chau MJ, Guduru Z, Gerhardt GA, van Horne CG. Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design. BMJ Neurology Open 2022;4:e000301.

54. Jessen KR, Mirsky R. The success and failure of the Schwann cell response to nerve injury. Front Cell Neurosci. 2019;13:33.

55. Jessen KR, Mirsky R, Lloyd AC. Schwann cells: development and role in nerve repair. Cold Spring Harb Perspect Biol. 2015;7(7):a020487.

56. Jessen KR, Arthur-Farraj P. Repair Schwann cell update: adaptive reprogramming, EMT, and stemness in regenerating nerves. Glia. 2019;67(3):421–37.

57. Allodi I, Udina E, Navarro X. Specificity of peripheral nerve regeneration: interactions at the axon level. Prog Neurobiol. 2012;98(1):16–37.

58. Blesch A, Lu P, Tsukada S, Alto LT, Roet K, Coppola G, Geschwind D, Tuszynski MH. Conditioning lesions before or after spinal cord injury recruit broad genetic mechanisms that sustain axonal regeneration: superiority to camp-mediated effects. Exp Neurol. 2012;235(1):162–73.

59. Roberson MD, Toews AD, Bouldin TW, Weaver J, Giones ND, Morell P. NGFR-mRNA expression in sciatic nerve: a sensitive indicator of early stages of axonopathy. Brain Res Mol Brain Res. 1995;28(2):231–38.

60. Rosenberg AF, Wolman MA, Franzini-Armstrong C, Granato M. In vivo nerve-macrophage interactions following peripheral nerve injury. J Neurosci. 2012;32(11):3898–3909.

61. Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res. 2015;1619:1–11.

62. Ferrante CJ, Leibovich SJ. Regulation of macrophage polarization and wound healing. Adv Wound Care (New Rochelle). 2012;1(1):10–16.

63. Chen P, Piao X, Bonaldo P. Role of macrophages in Wallerian degeneration and axonal regeneration after peripheral nerve injury. Acta Neuropathol. 2015;130(5):605–18.

64. Tsuyuzaki K, Sato H, Sato K, Nikaio I. Benchmarking principal component analysis for large-scale single-cell RNA-sequencing. Genome Biol. 2020;21(1):9.

65. Li W, Englund E, Widner H, Mattsson B, van Westen D, Lätt J, Rehncrona S, Brundin P, Björklund A, Lindvall O, Li J-Y. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proceedings of the National Academy of Sciences. 2016;113(23):6544.

66. Lindvall O. Clinical translation of stem cell transplantation in Parkinson’s disease. J Intern Med. 2016;279(1):30–40.

67. Olanow CW, Freeman T, Kordower J. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001;345(2):146.

68. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med. 2008;14(5):507–509.

69. Grambalova Z, Kaisera M, Vastik M, Mensikova K, Otruba ND, Morell P. NGFR-mRNA expression in sciatic nerve: a sensitive indicator of early stages of axonopathy. Brain Res 1998;2(2):173–4.

70. Zis P, Grunewald RA, Chaudhuri RK, Hadjiavassiou M. Peripheral neuropathy in idiopathic Parkinson’s disease: a systematic review. J Neurol Sci. 2017;378:204–209.

71. Chau MJ, Deveau TC, Gu X, Kim YS, Xu Y, Yu SP, Wei L. Delayed and repeated intranasal delivery of bone marrow stromal cells increases regeneration and functional recovery after ischemic stroke in mice. BMC Neurosci. 2018;19(1):20.

72. Chau MJ, Deveau TC, Song M, Gu X, Chen D, Wei L. iPSC Transplantation increases regeneration and functional recovery after ischemic stroke in neonatal rats. Stem Cells. 2014;32(12):3075–87.

73. Chau M, Deveau TC, Song M, Wei ZZ, Gu X, Yu SP, Wei L. Transplantation of iPSC-cell-derived neural progenitors overexpressing SDF-1alpha increases regeneration and functional recovery after ischemic stroke. Oncotarget. 2017;8(57):97537–53.